PURPOSE: To report pathological outcomes and predictors of adverse pathology in @entity1 undergoing radical prostatectomy (RP) after an initial period of @entity3457 ( @entity3457 ). MATERIALS AND METHODS: We studied pathological outcomes in @entity1 who underwent RP after some time on @entity3457 . Pathological outcomes were compared between @entity1 with and without evidence of disease reclassification on @entity3457 . Rates of adverse pathology (defined as pathological stage>= pT3a, RP Gleason >= 4+3, or lymph node involvement) were determined, and were compared depending on the variable that defined disease reclassification. RESULTS: Of 1086 @entity1 enrolled in @entity3457 , 130 (12.0%) underwent RP after a median time of 1.96 years (range 0.55-12.26 years) on @entity3457 . 97 (74.6%) of these @entity1 had evidence of disease reclassification on @entity3457 . Rates of adverse pathology were greater in @entity1 with evidence of reclassification compared to those without (p=0.05). Among @entity1 with disease reclassification, rates of adverse pathology ranged from 23.8% to 44.7% depending on the variable used to define reclassification. Longer time on @entity3457 was not associated with adverse pathology (p=0.68). CONCLUSIONS: Adverse pathology after RP is more common in @entity1 with evidence of disease reclassification on @entity3457 compared to those undergoing RP for other reasons. However, we identified varying outcomes among these @entity1 depending on the criterion that defined reclassification. These data may enable identification of @entity1 who can safely continue on @entity3457 despite evidence of disease reclassification.

Predictors of Adverse Pathology in XXXX Undergoing Radical Prostatectomy Following Initial Active Surveillance.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity3457 :: ('OMIM:612348', 'Disease') :: ['active surveillance', 'AS']
@entity1 :: (9606,Species) :: ['Men']
